"More than 10 million Americans have trouble distinguishing red from green or blue from yellow, and there's no treatment for colorblindness." reports National Public Radio (NPR). "A biotech company and two scientists hope to change that. On Wednesday, Avalanche Biotechnologies in Menlo Park and the University of Washington in Seattle announced a licensing agreement to develop the first treatment for colorblindness. The deal brings together a gene therapy technique developed by Avalanche with the expertise of vision researchers at the University of Washington. 'Our goal is to be treating colorblindness in clinical trials in patients in the next one to two years,' says Thomas Chalberg, the founder and CEO of Avalanche." Read more or listen to the story.